Tocagen streamlines pivotal plans; Wave Life Sciences cuts ribbon on new manufacturing plant

→ San Diego-based Tocagen $TOCA has streamlined its Phase III plans for Toca 511 & Toca FC as a new therapy for brain cancer. The biotech is doing away with the original Phase II/III approach and going straight into a pivotal study.

→ Cambridge, MA-based Wave Life Sciences has opened a new 90,000-square-foot manufacturing facility in Lexington. Over the longterm the company says the facility has room for up to 200 staffers. “The expansion of our manufacturing capabilities is a critical milestone in our evolution as a clinical-stage company and a further commitment to our pledge of providing much needed therapies to patients living with serious, genetically-defined diseases,” said CEO Paul Bolno.

Versartis $VSAR has called in Cowen to look for some new programs to help diversify its pipeline.

The best place to read Endpoints News? In your inbox.

Full-text daily reports for those who discover, develop, and market drugs. Join 21,000+ biopharma pros who read Endpoints News by email every day.

Free Subscription